Nevertheless, patients with triple-negative breast cancer (TNBC) frequently have few pharmacological treatment options, in contrast to hormone receptor-driven breast cancer, and efavirenz has been found to be a promising anticancer treatment for treating prostate and pancreatic cancers. This evidence concerns the gene NR4A1 and familial pancreatic carcinoma.